Novartis India Ltd.
|BSE: 500672||Sector: Health care|
|NSE: NOVARTIND||ISIN Code: INE234A01025|
|BSE 15:45 | 16 Mar||618.50||
|NSE 05:30 | 01 Jan||Novartis India Ltd|
|Mkt Cap.(Rs cr)||1,528|
|Mkt Cap.(Rs cr)||1527.70|
Novartis India Ltd. (NOVARTIND) - Latest News & Headlines
8.55 pm | 12 Mar 2018 | Reuters
Narasimhan, who took over as CEO in February, is emphasising the role of digital technology in helping Novartis come up with winning new therapies
8.01 pm | 29 Jan 2018 | Press Trust of India
Novartis India also announced the appointment of Jawed Zia as vice chairman and managing director of the company effective March 1, 2018
8.55 pm | 27 Jan 2018 | Business Standard
It would have a Rs 30 bn turnover this financial year; 80% of its revenue comes from domestic market
12.58 am | 14 Nov 2017 | Business Standard
The face of MNC drug firms in India and champion of IPR protection, he oversaw the Swiss giant's India expansion, its forays into new therapies and se...
5.04 pm | 25 Sep 2017 | Press Trust of India
Shares of Novartis India were trading 6.85% down at Rs 635.85 apiece on BSE
2.36 pm | 25 Sep 2017 | Business Standard
The board approved share buyback at a price of Rs 670 per share, against Friday's close of Rs 683 on BSE.
9.54 am | 21 Sep 2017 | Business Standard
So far in 2017, the stock under-performed the market by falling 24% as compared to 22% rise in the S&P BSE Sensex till Wednesday.